Current concepts in combination therapy for the treatment of hypertension: Combined calcium channel blockers and RAAS inhibitors

Integrated Blood Pressure Control

Volumn 2, Issue , 2009, Pages 55-62

  Rubio Guerra, Alberto Francisco ^a   Castro Serna, David ^a   Elizalde Barrera, Cesar I ^a   Ramos Brizuela, Luz M ^a  

^a Hospital General de Ticoman SS DF   (Mexico)

Author keywords

Adherence; Calcium channel blockers; Fixed dose combination; Hypertension; Renin angiotensin aldosterone system inhibitors

Indexed keywords

ALISKIREN; AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT PLUS DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DELAPRIL PLUS MANIDIPINE; DIHYDROPIRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE PLUS RAMIPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; LISINOPRIL; OLMESARTAN; PERINDOPRIL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITOR; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ANKLE EDEMA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; REVIEW; STROKE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 77953441984     PISSN: None     EISSN: 11787104     Source Type: Journal    
DOI: 10.2147/ibpc.s6232     Document Type: Review

References (49)

1. The Seventh report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood pressure. JNC 7. Hypertension. 2003;42:1206-1252.
2. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults, 1999-2004. Hypertension. 2007;49:69-75.
3. Rosas M, Lara A, Pastelín G, Velásquez O, Martínez J, Mendez A. Re-encuesta nacional de hipertensión arterial. Consolidación Mexicana de los factores de riesgo cardiovascular. Cohorte Nacional de Seguimiento. Arch Cardiol Mex. 2005;75:96-111.
4. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag. 2008;4:653-664.
5. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290-300.
6. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin ii type 1 receptor blocker. J Clin Hypertens. 2008; 10(1 Suppl 1):27-32.
7. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. Guidelines for the management of arterial hypertension. J Hypertens. 2007;25:105-188.
8. Dahlöf B. Management of cardiovascular risk with RAS inhibitor/ CCB combination therapy. J Hum Hypertens. 2009;23:77-85.
9. Rubio AF, Lozano JJ, Vargas G, Rodríguez L, Ramos LM, Escalante B. Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy. Clin Exp Hypertens. 2006;28:619-624.
10. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386-392.
11. Llenen FH, Nwachuku CH, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. 2006;48:374-384.
12. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
13. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906.
14. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
15. Rubio AF, Arceo A. Lozano JJ, Vargas G, Rodríguez L, Ramos LM. Efficacy of a fixed-dose combination of trandolapril-verapamil in patients with stage-2 hypertension inadequately controlled by monotherapy. Clin Drug Invest. 2005;25:445-451.
16. Fogari R, Malamani GD, Zoppi A, Mugellini A, Rinaldi A, Vanasia A. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertyensive patients. J Hum Hypertens. 2003;17:207-212.
17. Parati G. Optimization of hypertension management: The role of angiotensin receptor blocker-calcium channel blocker combinations. J Cardiovasc Pharmacol. 2009;53:352-358.
18. Poldermans D, Glazer R, Karagiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279-289.
19. Alleman Y, Fraile B, Lambert M, Barbier M, Ferber PH, Izzo JL. Previous monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study J Clin Hypertens (Greenwich). 2008;10:185-194.
20. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587-604.
21. Littlejohn TW, Majul CR, Olvera R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich). 2009;11:207-213.
22. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren. A 12-Month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009;119:417-425.
23. Littlejohn TW, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin. 2009;25:951-959.
24. Gasic S, Wagner O, Fasching P, et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type 2 diabetic patients with microalbuminuria. Am J Hypertens. 1999;12:217-222.
25. Park JK, Fiebeler A, Muller DN, et al. Lacidipine inhibits adhesion molecule and oxidase expression independent of blood pressure reduction in angiotensin-induced vascular injury. Hypertension. 2002;39:680-689.
26. Siragy HM, Xue Ch, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-α production after cardiac ischemia. J Cardiovasc Pharmacol. 2006;47: 636-642.
27. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Rodríguez-Lopez L, Escalante-Acosta BA. The effect of trandolapril and its fixeddose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens. 2008;30:682-688.
28. Rubio AF, Vargas H, Lozano JJ, Escalante BA. Corrrelation between circulating adhesión molecules levels and albuminuria in type 2 diabetic hypertensive patients. Kidney Blood Press Res. 2009;32:106-109.
29. Bakris GL, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592-2597.
30. Bakris GL, Molitch M, Sowers J, et al. Reversal of new onset diabetes by nondiuretic based fixed-dose antihypertensive drug combinations. Results of STAR 6-month extension (STAR-LET). J Cardiomet Syndr. 2008;3:18-25.
31. Rubio AF, Arceo A, Vargas G, Rodríguez L, Lozano J, Treviño C. The Effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care. 2004;27:1688-1691.
32. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Rodríguez-Lopez L, Escalante-Acosta BA. The effect of trandolapril and its fixed-dose combination with verapamil on resistin levels in hypertensive patients with type 2 diabetes. J Hypertens. 2008;26:S476.
33. Takata Y, Osawa H, Kurata M, et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension. 2008;51:534-539.
34. Roca-Cusachs A, Schmieder RE, Triposkiadis F, et al. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J Hypertens. 2008;26:813-818.
35. Tatti P, Guarisco R, Pahor M, et al. Outcome results of the Fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-602.
36. Winer N, Folker A, Murphy JA, et al. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005;8:87-92.
37. Gross JL, De Azevedo MJ, Silveiro SP. Diabetic nephropathy: diagnosis, prevention and treatment. Diabetes Care. 2005;28:176-188.
38. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002.
39. Bakris G, Weir MR, DeQuatro V, Mc-Mahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:1283-1289.
40. Rubio AF, Treviño CJ, Vargas G, Narváez JL, Lozano JJ, Rodríguez L. Renoprotective effects of the combination trandolapril/verapamil in patients with type 2 diabetes mellitus and hypertension. Clin Drug Invest. 2002;22:541-546.
41. Ruggenenti P, Fassi A, Ilieva AP. Preventing microalbuminuria in type 2 diabetic patients. N Engl J Med. 2004:351:1941-1951.
42. Jasik M, Niebisz AB, Kosior DA, Karnafel W. Nephroprotective effect of trandolapril and verapamil in normotensive type 1 diabetics - a 12-month follow-up study. Diabetologia Do wiadczalna i Kliniczna. 2006;6:6-10.
43. Bakris GL, Toto RD, McCullough PA, Tocha R, Purkayastha D, Davis P; On behalf of the GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008;73:1303-1309.
44. Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15:1042-1049.
45. Toto RD, Tian M, Fakouhi K, Champion A, Bacher P. Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. J Clin Hypertens (Greenwich). 2008;10:761-769.
46. Boero R, Rollino C, Massara C, Berto IM, Perosa P, Vagelli G. The verapamil versus amlodipine in nondiabetic nephropathies treated with Trandolapril (VVANNTT) study. Am J Kidney Dis. 2003;42:67-75.
47. Giunti S, Cooper M. Management strategies for patients with hypertension and diabetes: why combination therapy is critical. J Clin Hypertens (Greenwich). 2006;8:108-113.
48. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
49. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve compliance: a meta-analysis. Am J Med. 2007;120:713-719.